Fenfluramine was administered to subgroups of high and low functioning autistic outpatients using a double-blind, placebo-controlled crossover design. Blood serotonin concentrations decreased an average of 60% after 16 weeks on medication for all subjects regardless of premedication concentrations. Reductions in hyperactivity and motor symptoms and improved attention were noted in both patient subgroups. Improved social awareness was seen only in high functioning autistic patients. No significant improvements were observed in intellectual functioning, nor were there any meaningful changes in clinician ratings of primary autistic disturbances.
|Original language||English (US)|
|Number of pages||5|
|Journal||Journal of the American Academy of Child and Adolescent Psychiatry|
|State||Published - Jan 1 1987|